Xenon Pharmaceuticals reported that azetukalner met the primary endpoint in a Phase 3 trial, significantly reducing the frequency of a common seizure type versus placebo and exceeding the effect seen in prior mid‑stage data. The company said it plans to seek FDA approval in the third quarter, putting azetukalner on an accelerated commercial track if regulators concur with the trial’s design and results. The success strengthens Xenon’s position in epilepsy therapeutics and will invite competitive scrutiny as larger players weigh market entry strategies.